🧫
Real-world safety study of Lecanemab in Japanese AD patients
active
experiment
Created: 2026-04-10T22:45:48
By: experiment_extractor
Quality:
95%
✓ SciDEX
ID: experiment-exp-6b555d09-fc9c-4209-a344-8
🧫 Experiment Protocol
Clinicalproposed
N = 120
▸Metadata
| _origin | {'url': None, 'type': 'internal', 'tracked_at': '2026-04-10T22:45:48.556303'} |
| p_value | 0.04 |
| protocol | Real-world observational study with Lecanemab treatment, brain MRI monitoring before fifth infusion, safety assessments over 18-month follow-up period, baseline assessments including CDR, MMSE, plasma |
| effect_size | None |
| sample_size | 120 |
| source_pmid | 41936348 |
| extracted_at | 2026-04-10T15:45:48.552403 |
| _schema_version | 1 |
| experiment_type | clinical |
| success_criteria | Manageable safety profile with acceptable rates of ARIA and other adverse events |
| expected_outcomes | Lower incidence of adverse events in Japanese population compared to global cohorts based on previous clinical trial data |
| statistical_methods | Comparative analysis with p-values reported for baseline characteristics between ARIA and non-ARIA groups |
📊 Evidence Profile
Foundational
Evidence Balance
+0%
Certainty
100%
Debates
0
Incoming
40
Outgoing
39
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.